XYXuecheng Yang

Xuecheng Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xuecheng Yang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Yuefeng Jia

    Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China

    6 shared publications
  • Guipeng Wang

    Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China

    5 shared publications
  • Haitao Niu

    The Affiliated Hospital of Qingdao University

    5 shared publications
  • Haotian Du

    Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China

    5 shared publications
  • Dan Li

    Key Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China

    3 shared publications
  • Liping Wang

    Key Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China

    3 shared publications

Latest Publications

  • Open Access

    Favorable performance of DGPR1008, a novel PSMA-targeted near-infrared fluorescent probe, for image-guided prostate cancer surgery in experimental models

    by Peng Li, Shengxian Li, Ying Xu, Yuanyuan Yan, Jiupeng Li, Mingxin Zhang, Gang Shen, Jing Zhao, Xuecheng Yang

    Background: Near-infrared (NIR) fluorescence-guided surgery has shown promise for prostate cancer (PCa). Despite several prostate-specific membrane antigen (PSMA)-targeted NIR probes entering clinical trials, none have received approval to date, highlighting the continuing need for novel agents with improved pharmacokinetic and imaging properties to support NIR fluorescence-guided surgery. DGPR1008, a newly designed PSMA-targeted NIR probe, has been proposed as a potential candidate probe. Consequently, this study primarily aimed to characterize the binding specificity of DGPR1008 to PSMA and evaluate its imaging and pharmacological profiles. A secondary aim was to compare its performance with that of the already clinically evaluated probe OTL78 in animal models. Methods: The PSMA-binding specificity of DGPR1008 was assessed in vitro in three PCa cell lines. Also, in vivo tumor targeting and fluorescence imaging, along with assessment of the biodistribution, pharmacokinetics, excretory clearance, and toxicity of DGPR1008, were performed in animal models. Finally, the pharmacokinetics, tissue distribution, imaging contrast, and tumor-to-background ratios of DGPR1008 were compared with those of the reference probe OTL78 at various time points post-injection. Results: Binding assays performed in the three PCa cell lines demonstrated the high affinity of DGPR1008 for PSMA. Meanwhile, the in vivo tests showed that DGPR1008 achieved selective tumor accumulation and rapid non-target clearance. Compared to the reference probe OTL78, DGPR1008 exhibited stronger, more persistent tumor fluorescence and tumor-to-background contrast in mice bearing subcutaneous xenografts. Furthermore, DGPR1008 displayed favorable pharmacokinetics and excretion profiles, with a notably faster plasma clearance than the reference probe OTL78. Conclusion: DGPR1008 demonstrated high PSMA specificity in vitro and favorable imaging performance in a PCa xenograft mouse model. Together with its favorable pharmacokinetic and safety profiles, these findings support the use of DGPR1008 as a promising real-time NIR fluorescence imaging probe for guiding PCa surgery with potential for clinical translation.

  • Open Access

    Artificial Intelligence–Powered Decision Support for Prostate Cancer: A Patient-Question–Driven Multimodal Integration Platform (Preprint)

    by Shi Qiu, Mincheng Piao, Xuecheng Yang, Shengxian Li

    UNSTRUCTURED We developed and validated a patient-question–driven multimodal platform that maps natural language clinical queries to ten validated prostate cancer prediction models across five decision stages, achieving a correct model invocation rate of 96% (96/100) across 100 simulated scenarios.

  • Open Access

    Preoperative predictors about lymph node metastasis and biochemical recurrence in high-risk prostate cancer patients: a clinic pathological retrospective study

    by Chuanyu Wang, Guipeng Wang, Lihua Xiao, Haotian Du, Youcheng Xu, Shengxian Li, Xuecheng Yang

    To explore the predictive value of the ratio of high grade cores and other preoperative factors in predicting lymph node metastasis and biochemical recurre

  • Open Access

    Nanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy

    by Yi Qiao, Lingyu Wei, Yinjie Su, Qinyuan Tan, Xuecheng Yang, Shengxian Li

    The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway plays a critical role in triggering innate and adaptive immune responses through type I interferon activation and immune cell recruitment, holding significant promise for cancer therapy. While STING activators targeting this pathway have been developed, their clinical application is hindered by challenges such as poor membrane permeability, rapid degradation, suboptimal pharmacokinetics, off-target biodistribution, and toxicity. Nanoparticle-based delivery systems offer a promising solution by enhancing the stability, circulation time, tumor accumulation, and intracellular release of STING activators. Furthermore, combining nanoparticle-delivered STING activators with radiotherapy, chemotherapy, phototherapy, and other immunotherapies enables synergistic antitumor effects through multimodal mechanisms, addressing resistance to monotherapies and reducing risks of recurrence and metastasis. This review outlines the immunomodulatory mechanisms of the cGAS-STING pathway, surveys current STING-targeted activators, and comprehensively discusses recent advances in nanoparticle-mediated delivery strategies for STING activation. Additionally, we explore combinatorial approaches that integrate STING-targeted nanotherapies with conventional and emerging treatments. Finally, we highlight the current status, prospects, and challenges of nanoparticle-based STING activation for cancer immunotherapy.


  • Open Access

    Photodynamic therapy for the precise treatment of localized prostate cancer

    by Youcheng Xu, Qinyuan Tan, Chong Sun, Yuefeng Jia, Shengxian Li, Xuecheng Yang

    Over the past 20 years, early diagnosis of prostate cancer has become increasingly prevalent due to the promotion of prostate-specific antigens, and its treatment has become a focal point. However, there are some drawbacks associated with therapies for early prostate cancer, such as active surveillance and radical prostatectomy, which may include urinary incontinence, erectile dysfunction, and urinary tract infection. In contrast, photodynamic therapy (PDT) is introduced into the treatment of prostate cancer because of its advantages, such as high precision to tumor cells, low toxicity, and no radiation. Compared to radical prostatectomy, the PDT has low risk and minimal trauma. Although PDT is in the early stages of clinical development, it holds promise for the effective treatment of localized prostate cancer. Herein, we reviewed studies on the mechanisms of PDT and photosensitizers for prostate cancer. Given the rapid development of nanotechnology, photosensitizers wrapped by nanomaterials have emerged as new option with significant advantages, particularly of in achieving high tumor selectivity using functional nanomaterials. Numerous PDT clinical trials on prostate cancer have been conducted worldwide. We also reviewed the results of a few photosensitizers in these clinical trials. However, a few limitations and challenges regarding PDT for prostate cancer still exist. In addition, future development and potential clinical application strategies of future PDT are predicted.


  • Open Access

    Predictive model for PSA persistence after radical prostatectomy using machine learning algorithms

    by Haotian Du, Guipeng Wang, Yongchao Yan, Shengxian Li, Xuecheng Yang

    Objective: To evaluate the efficacy of a machine learning model for predicting prostate-specific antigen (PSA) persistence after radical prostatectomy (RP).Methods: Data from 470 patients who underwent RP at the Affiliated Hospital of Qingdao University from January 2018 to June 2021 were retrospectively analyzed. Ten risk factors, including age, body mass index (BMI), preoperative PSA, biopsy Gleason score, total prostate specific antigen density (PSAD), clinical tumor stage, clinical lymph node status, seminal vesicle invasion, capsular invasion and positive surgical margin, were included in the analysis. The data were randomly divided into a training set and a test set at a ratio of 7:3, and seven different machine learning algorithms were compared. The confusion matrix, receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) were used to evaluate the diagnostic performance of the model, and the random forest algorithm found to be the optimal prediction model.Results: In the entire cohort, 142 (30.21%) patients developed PSA persistence. Based on all included risk factors, the random forest model had the best effect among the seven models, with an AUC of 0.8607 in the training set and 0.8011 in the test set. The feature importance results showed that capsular invasion, positive surgical margin, preoperative PSA and biopsy Gleason score were the four most important risk factors for PSA persistence after RP.Conclusion: The Random Forest algorithm performed excellently in this study and can be used to construct a predictive model for PSA persistence. By incorporating clinical data from the Asian region and exploring the risk factors for PSA persistence, this study contributes to the existing research and aids clinicians in assessing the risk of PSA persistence occurrence, enabling timely treatment planning and improving patient prognosis.


  • Open Access

    Predictive model of positive surgical margins after radical prostatectomy based on Bayesian network analysis

    by Guipeng Wang, Haotian Du, Fanshuo Meng, Yuefeng Jia, Xinning Wang, Xuecheng Yang

    Objective: This study aimed to analyze the independent risk factors for marginal positivity after radical prostatectomy and to evaluate the clinical value of the predictive model based on Bayesian network analysis.Methods: We retrospectively analyzed the clinical data from 238 patients who had undergone radical prostatectomy, between June 2018 and May 2022. The general clinical data, prostate specific antigen (PSA)–derived indicators, puncture factors, and magnetic resonance imaging (MRI) characteristics were included as predictive variables, and univariate and multivariate analyses were conducted. We established a nomogram model based on the independent predictors and adopted BayesiaLab software to generate tree-augmented naive (TAN) and naive Bayesian models based on 15 predictor variables.Results: Of the 238 patients included in the study, 103 exhibited positive surgical margins. Univariate analysis revealed that PSA density (PSAD) (P = 0.02), Gleason scores for biopsied tissue (P = 0.002) and the ratio of positive biopsy cores (P < 0.001), preoperative T staging (P < 0.001), and location of abnormal signals (P = 0.002) and the side of the abnormal signal (P = 0.009) were all statistically significant. The area under curve (AUC) of the established nomogram model based on independent predictors was 73.80%, the AUC of the naive Bayesian model based on 15 predictors was 82.71%, and the AUC of the TAN Bayesian model was 80.80%.Conclusion: The predictive model of positive resection margin after radical prostatectomy based on Bayesian network demonstrated high accuracy and usefulness.


  • Open Access

    Prediction model of gleason score upgrading after radical prostatectomy based on a bayesian network

    by Guipeng Wang, Xinning Wang, Haotian Du, Yaozhong Wang, Liguo Sun, Mingxin Zhang, Shengxian Li, Yuefeng Jia, Xuecheng Yang

    Objective: To explore the clinical value of the Gleason score upgrading (GSU) prediction model after radical prostatectomy (RP) based on a Bayesian network. Methods: The data of 356 patients who underwent prostate biopsy and RP in our hospital from January 2018 to May 2021 were retrospectively analysed. Fourteen risk factors, including age, body mass index (BMI), total prostate-specific antigen (tPSA), prostate volume, total prostate-specific antigen density (PSAD), the number and proportion of positive biopsy cores, PI-RADS score, clinical stage and postoperative pathological characteristics, were included in the analysis. Data were used to establish a prediction model for Gleason score elevation based on the tree augmented naive (TAN) Bayesian algorithm. Moreover, the Bayesia Lab validation function was used to calculate the importance of polymorphic Birnbaum according to the results of the posterior analysis and to obtain the importance of each risk factor. Results: In the overall cohort, 110 patients (30.89%) had GSU. Based on all of the risk factors that were included in this study, the AUC of the model was 81.06%, and the accuracy was 76.64%. The importance ranking results showed that lymphatic metastasis, the number of positive biopsy cores, ISUP stage and PI-RADS score were the top four influencing factors for GSU after RP. Conclusions: The prediction model of GSU after RP based on a Bayesian network has high accuracy and can more accurately evaluate the Gleason score of prostate biopsy specimens and guide treatment decisions.


  • Open Access

    Prediction model of Gleason score upgrading after radical prostatectomy based on a Bayesian network

    by Guipeng Wang, Xinning Wang, Haotian Du, Yaozhong Wang, Liguo Sun, Mingxin Zhang, Shengxian Li, Yuefeng Jia, Xuecheng Yang

    Objective To explore the clinical value of the Gleason score upgrading (GSU)prediction model after radical prostatectomy (RP) based on a Bayesian network. Methods The data of 356 patients who underwent prostate biopsy and RP in our hospital from January 2018 to May 2021 were retrospectively analysed. Fourteen risk factors,including age, body mass index (BMI), total prostate-specific antigen (tPSA), prostate volume, total prostate-specific antigen density (PSAD), the number and proportion of positive biopsy cores, PI-RADS score, clinical stage and postoperative pathological characteristics, were included in the analysis. Data were used to establish a prediction model for Gleason score elevation based on the tree augmented naive (TAN) Bayesian algorithm. Moreover, the Bayesia Lab validation function was used to calculate the importance of polymorphic Birnbaum according to the results of the posterior analysis and to obtain the importance of each risk factor. ResultsIn the overall cohort, 110 patients (30.89%) had GSU. Based on all of the risk factors that were included in this study, the AUC of the model was 81.06%, and the accuracy was 76.64%. The importance ranking results showed that lymphatic metastasis, the number of positive biopsy cores, ISUP stage and PI-RADS score were the top four influencing factors for GSU after RP. ConclusionsThe prediction model of GSU after RP based on a Bayesian network has high accuracy andcan more accurately evaluate the Gleason score of prostate biopsy specimens and guide treatment decisions.